An effective, side effect-free topical emollient treatment for atopic dermatitis made from a sustainably procured seaweed extract

Projektinformationen

Fucoderm

ID Finanzhilfevereinbarung: 744737

DOI

10.3030/744737

Projekt abgeschlossen

EK-Unterschriftsdatum 6 Dezember 2016

Startdatum 1 Dezember 2016

Enddatum 31 März 2017

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

GLYCOMAR LIMITED
United Kingdom

Periodic Reporting for period 1 - Fucoderm (An effective, side effect-free topical emollient treatment for atopic dermatitis made from a sustainably procured seaweed extract)

Berichtszeitraum: 2016-12-01 bis 2017-03-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

GlycoMar intends to develop a novel topical cream for the management of mild to moderate eczema. The new product, ‘Fucobase’ will be suitable for long-term use and safe for both adults and children. The key objectives of the project are to finalise the Fucobase formulation, validate its safety and efficacy in humans, and commercialise the product as a CE certified medical device.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

Throughout the duration of the Phase I project, GlycoMar reviewed the product development plan, secured partners for further product development, expanded their knowledge of the eczema market and established a commercialisation strategy. The Phase 1 feasibility assessment established that a development plan for the Fucobase product is technically and commercially viable, and that implementation of an industrialisation and commercialisation plan should be pursued. SME Instrument Phase 2 funding could provide the correct amount of funding and support to allow the stated activities to be implemented successfully.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

The proposed Fucobase product will provide mild to moderate eczema sufferers, with an effective, natural and universal treatment. Unlike many existing products, it will be suitable for use in both adults and children, due to minimal side effects. Fucobase will therefore contribute to a sustainable and innovative healthcare system in Europe by reducing the large medical and social costs caused by this common disease.

Fucobase